Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
MAXIBOLIN (ethylestrenol) is an oral anabolic steroid approved in 1965 by Merck & Co. as an elixir formulation. The drug mechanism of action and specific indications are not documented in available data, though historical use suggests anabolic/protein-building applications. It represents a legacy small-molecule product from the early steroid era.
Product is in late-stage lifecycle with minimal recent commercial activity; team likely focused on managed decline and compliance rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MAXIBOLIN offers limited career advancement opportunities due to its mature, declining lifecycle stage and minimal linked job postings. Roles available focus on regulatory maintenance, compliance, and managed decline rather than brand building or innovation.
Worked on MAXIBOLIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.